Diagnostic detection device

• US 8,211,711 B2
• Filed: 06/25/2010
• Issued: 07/03/2012
• Est. Priority Date: 03/01/2007
• Status: Active Grant

• Current Assignee: Church & Dwight Company Incorporated
• Original Assignee: Church & Dwight Company Incorporated
• Inventors: Nazareth, Albert, Snowden, Timothy, Cheng, Yea-shun
• Primary Examiner(s): Chin, Chris L
• Application Number:
  US12/823,949
• Publication Number:
  US 20100261293A1
• Time in Patent Office: 739 Days
• Field of Search: None
• US Class Current: 436/514
• CPC Class Codes: G01N 2333/59 Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• CPC Class Codes: G01N 33/54388 based on lateral flow
• CPC Class Codes: G01N 33/558 using diffusion or migration of antigen or antibody immunochromatographic test strips G01N33/54387
• CPC Class Codes: Y10S 435/805 Test papers
• CPC Class Codes: Y10S 435/81 Packaged device or kit
• CPC Class Codes: Y10S 435/97 Test strip or test slide
• CPC Class Codes: Y10S 436/805 Optical property
• CPC Class Codes: Y10S 436/81 Tube, bottle, or dipstick

Abstract

The invention comprises a device for detecting an analyte in a liquid sample deposited on a first portion of the device for transport to a second portion of the device that is in fluid contact with the first portion. In specific embodiments, the device comprises a labeled conjugate comprising a binding member reactive with a first epitope of the analyte and a label comprising a gold colloid, preferably having a mean particle size of 50 nm to 100 nm. In further embodiments, the device comprises a capture component comprising polymerized streptavidin. The diagnostic device is particularly useful in the preparation of pregnancy test kits.

Claims

1. A device for detecting an analyte in a liquid sample deposited on a first portion of the device for transport to a second portion of the device that is in fluid contact with the first portion, wherein the device comprises:

A) in the first portion thereof, a labeled conjugate comprising a binding member reactive with a first epitope of the analyte and a label comprising colloidal gold particles having a mean particle size of at least about 50 nm prior to formation of the labeled conjugate; and

B) in the second portion thereof, a capture component that is directly or indirectly reactive with a second epitope of the analyte.

2. The device of claim 1, wherein the colloidal gold particles have a mean particle size of about 50 nm to about 100 nm.

3. The device of claim 1, wherein the colloidal gold particles have a mean particle size of about 55 nm to about 85 nm.

4. The device of claim 1, wherein the colloidal gold particles have a mean particle size of about 60 nm to about 80 nm.

5. The device of claim 1, wherein the colloidal gold particles have a mean particle size of about 60 nm to about 75 nm.

6. The device of claim 1, wherein the capture component is directly reactive with a second epitope of the analyte.

7. The device of claim 1, wherein the capture component is indirectly reactive with a second epitope of the analyte.

8. A method for determining the presence of an analyte in a liquid sample comprising:

A) providing an analyte detection device comprising a substrate with a first portion comprising colloidal gold having a mean particle size of at least about 50 nm releasably immobilized thereon and a second portion in fluid communication with the first portion and comprising a capture component immobilized thereon;

B) adding a liquid sample to the first portion of the device;

C) allowing the liquid sample to flow across the first portion and the second portion of the substrate; and

D) determining the presence of the analyte in the liquid sample by visual inspection of the second portion of the substrate, wherein the presence of the analyte is indicated by the presence of color development in the area wherein the capture component is immobilized caused by accumulation of the colloidal gold.

9. The method of claim 8, wherein the colloidal gold particles have a mean particle size of about 50 nm to about 100 nm.

10. The method of claim 8, wherein the colloidal gold particles have a mean particle size of about 55 nm to about 85 nm.

11. The method of claim 8, wherein the colloidal gold has a mean particle size of about 60 nm to about 80 nm.

12. The method of claim 8, wherein the colloidal gold particles have a mean particle size of about 60 nm to about 75 nm.

13. The method of claim 8, wherein the capture component comprises polymerized streptavidin.

14. The method of claim 13, wherein greater than 50% by weight of the polymerized streptavidin is at least about 100 kDa in size.

15. The method of claim 13, wherein the capture component is immobilized to the second portion through direct attachment of the polymerized streptavidin to the second portion.

16. The method of claim 13, wherein the capture component is immobilized to the second portion through indirect attachment of the polymerized streptavidin to the second portion.

17. The method of claim 16, wherein the indirect attachment is through an intermediate material selected from the group consisting of latex beads, immunoglobulins, bovine serum albumin, and combinations thereof.

18. The method of claim 8, wherein the color intensity caused by accumulation of the colloidal gold, when measured on a Biodot test apparatus, is at least 25% greater than the color intensity under the same conditions caused by accumulation of colloidal gold having a mean particle size of less than 50 nm.